AIM
ALXN

AIA Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

AIA Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$1.39M Buy
+12,100
New +$1.31M 0.32% 68

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AIA Investment Management's ALXN Position: Q3 2020 in Review

AIA Investment Management opened a new position in Alexion Pharmaceuticals (ALXN) in Q3 2020: 12,100 shares worth $1.39M. The stake represents 0.32% of the portfolio and ranks #68 among its holdings.

707 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

  • AIA Investment Management held 12,100 shares of Alexion Pharmaceuticals worth $1.39M as of Q3 2020.
  • Alexion Pharmaceuticals was a new AIA Investment Management position in Q3 2020.
  • Alexion Pharmaceuticals made up 0.32% of AIA Investment Management's portfolio in Q3 2020, its #68 holding.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on AIA Investment Management's 13F filing for Q3 2020, filed 16 Nov 2020.